RxDoctor Payments Data

Mark Koralewski, MD

Family Medicine · Atlanta, GANPI 1992720841

Payments from drug & device makers

$5,627in general payments, 2019–2025

Across 273 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1K
  • Viiv Healthcare Company$727
  • AbbVie$620
  • Pfizer$436
  • Lilly USA, LLC$432
  • Novo Nordisk$202
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$5,620100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,627 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$25,038
Medicare patients
86
Services billed
241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin22$32,597
OzempicSemaglutide19$25,731
EliquisApixaban13$20,398
FarxigaDapagliflozin Propanediol11$14,460
SynthroidLevothyroxine Sodium24$1,875
Atorvastatin Calcium181$1,282
Potassium Chloride18$1,092
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df11$1,044
Rosuvastatin Calcium102$857
Fluoxetine Hcl12$840
ValacyclovirValacyclovir Hcl14$814
Olmesartan Medoxomil36$711
Omeprazole30$631
Metoprolol Succinate50$630
Simvastatin43$570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$202$25,73119 claims
PfizerEliquis$436$20,39813 claims
AbbVieSynthroid$620$1,87524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →